Skip to main content

Advertisement

Table 4 Univariate analysis of prognostic factors for progression-free survival (PFS) and overall survival (OS) in HGG patients

From: Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with 68Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy

   PFS OS
  n (%) HR (95% CI) P value HR (95% CI) P value
SSTR2 IHC      
 Negative 19 (67.9) 1   1  
 Positive 9 (32.1) 0.161 (0.037 to 0.704) 0.015 0.083 (0.010 to 0.655) 0.018
Age      
  > 60 11 (39.3) 1   1  
  < 60 17 (60.7) 0.484 (0.190 to 1.233) 0.128 0.183 (0.053 to 0.631) 0.007
Oligodendroglioma component      
 No 21 (75.0) 1   1  
 Yes 7 (25.0) 0.592 (0.210 to 1.672) 0.322 0.361 (0.094 to 1.380) 0.137
IDH1      
 Wild type 19 (67.9) 1   1  
 Mutated 9 (32.1) 0.312 (0.102 to 0.950) 0.040 0.167 (0.036 to 0.770) 0.022
MGMT promoter      
 Unmethylated 5 (18.5) 1   1  
 Methylated 22 (81.5) 0.234 (0.073 to 0.753) 0.015 0.229 (0.061 to 0.859) 0.029
1p/19q co-deletion      
 No 24 (85.7) 1   1  
 Yes 4 (14.3) 0.780 (0.244 to 2.496) 0.675 0.390 (0.081 to 1.871) 0.239
EGFR amplification      
 No 20 (71.4) 1   1  
 Yes 8 (28.6) 2.083 (0.819 to 5.297) 0.124 3.131 (0.986 to 9.943) 0.053
  1. Results are expressed as hazard ratio (HR) with 95% confidence interval.